Find the latest AbbVie news related to customer service below. We do our best to screen the news provided here for relevance and accuracy, but the links to articles found here are from 3rd parties so occassionally less pertinent materials get published. Please feel free to contact us to report other relevant articles, or to let us know of any material that should be removed.
The global Divalproex Sodium market growing at a CAGR X.X% and the revenue value at USD XX.XXmillion in 2018 and is expected to reach USD XX.XX million in 2023. The Divalproex Sodium market report highlights major factor of current economic affairs ...
Abbott Laboratories Inc. and AbbVie Inc., the last defendants in the litigation over “low testosterone,” have reached a global settlement that resolves more than 4,000 cases. In an order on Monday, U.S. District Judge Matthew Kennelly of the Northern ...
JetBlue Airways Corporation (Nasdaq:JBLU) is a low-fare, low-cost passenger airline, which provides high-quality Customer Service primarily on point-to-point routes and is based in New York's John F. Kennedy International Airport. .JetBlue carries more ...
Hello, readers! This is Sy. The prospect of Amazon entering the medical arena may have, at least in part, helped set off a flurry of dealmaking among insurers, pharmacy benefits managers, and even retailers. The rumbles inched closer to reality when a ...
Please contact Customer Service. CLOSE. Porges cut his revenue and earnings expectations by 1%-2% and 2%, respectively, after 2019. He questioned whether Rova-T will ever get approved as it struggles with lung and blood toxicity. As a result, he ...
Good afternoon, readers! This is Sy. As Cliff mentioned yesterday, our 3rd annual Fortune Brainstorm Health conference came to a close Tuesday with a fascinating discussion between Arianna Huffington, NBA superstar Kevin Durant, and Rich Kleiman.
Biogen Inc. and an Illinois drugmaker said Friday that they are pulling their new treatment for multiple sclerosis from the market because a number of patients using it have suffered serious brain inflammation. Cambridge-based Biogen and its North ...
Global Testosterone Replacement Therapy Market Research Report 2018 provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly ...
Netflix has been on a massive run this year, and was so far extended from its latest buy point heading into the correction that no sell signal was ever triggered and no technical support levels were in question. Netflix shares are closing in on the ...
Recommended for you. Made-Again-in-USA: CEOs Ready to Bring Jobs Home If Nafta Dies · GE Picks Ex-FASB Chair, Former Industrial CEOs in Board Overhaul · Corbyn Rejects Second Referendum on Leaving EU: Brexit Update · Trump's Obamacare Changes to Push ...
AbbVie Inc. said Friday the new U.S. tax overhaul will slash its effective tax rate to 9% for 2018 and yield savings the drugmaker said it would use to return cash to shareholders and boost employee compensation. Shares of AbbVie jumped 10% to $118.90, ...
Drugmakers AbbVie Inc. and Amgen Inc. reached a patent-dispute settlement requiring Amgen to wait until 2023 to start selling a lower-priced copy of the world's top-selling drug, AbbVie's arthritis treatment Humira, in the U.S.. The deal could give ...
AbbVie risulta l'azienda farmaceutica con la più elevata reputazione in Italia. Con un incremento di 15,7 punti nello score, AbbVie sale dalla undicesima alla prima posizione della classifica di Italy Pharma RepTrak 2017, redatta da Reputation ...
L'azienda biofarmaceutica statunitense AbbVie conquista il primo posto nella classifica Pharma-RepTrak 2017 del Reputation Institute. Unica italiana nelle prime dieci posizioni è la Zambon. Lo stabilimento AbbVie di Campoverde di Aprilia. Leggi anche ...
AbbVie Inc. (ABBV - Free Report) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA. AbbVie is looking to get elagolix approved as an oral medicine for ...
AbbVie Inc. (ABBV - Free Report) announced that its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P), Mavyret, has been approved of in Canada for treating chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). It is ...
Kristoffer Tripplaar / Sipa USA. AbbVie Inc. filed a patent infringement lawsuit Wednesday against German rival Boehringer Ingelheim Pharmaceuticals Inc., the second case in Delaware that seeks to block sales of a less-expensive biosimilar version of ...
The Food and Drug Administration (FDA) approved the first-ever drug that can treat all six major strains of hepatitis C (or HCV) in just eight weeks on Thursday. The approval of AbbVie's Mavyret is bad news for competitors like biotech giant Gilead ...
AbbVie Inc. (NYSE:ABBV)'s latest quote $72.52 $0.01 -1.88% will find technical support in $71.81 a share and a breakdown below this region would be a significantly bearish signal for AbbVie Inc. traders. Any way you dice it, a dip below $71.1 a share ...
A federal jury in Chicago on Monday found AbbVie Inc. fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages. The verdict, which came in response to a ...
AbbVie misled an Oregon man about AndroGel's propensity for causing blood clots, a federal jury found. By Jef Feeley Bloomberg News July 24, 2017. WILMINGTON, Del. — AbbVie Inc. was ordered to pay $150 million to an Oregon man who accused the ...
A federal jury in East St. Louis, Ill., has awarded $15 million to a 10-year-old boy whose mother blamed his birth defect on AbbVie Inc.'s bipolar disorder drug Depakote that she took while pregnant, in the latest trial among hundreds of lawsuits over ...
AbbVie Inc.'s (ABBV - Free Report) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. (CHRS - Free Report) . So far this ...
AbbVie's Humira, the best-selling drug on the planet with a staggering $14 billion in 2016 sales, has lost a key patent battle with a prospective rival product by the small biotech Coherus Biosciences. The rheumatoid arthritis and psoriasis medicine ...
AbbVie Inc. (ABBV - Free Report) recently announced disappointing top-line results from two phase III studies evaluating its PARP inhibitor, veliparib in combination with chemotherapy (such as carboplatin and paclitaxel) for treatment of patients with ...
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more. ByAdam Feuerstein. Apr 17, 2017 10:51 AM EDT. Three pharma stocks that stand to benefit from the announcement by Eli Lilly & Co. (LLY - Get Report) and Incyte ...
AbbVie Inc.'s (ABBV - Free Report) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie's multi-utility TNF blocker drug, Humira. With this approval, Humira becomes the first and the ...
Best Workplaces Italia 2017: AbbVie è settima per la categoria grandi imprese nella classifica delle migliori aziende in cui lavorare e prima del settore farmaceutico. Leggi anche. 0. 0. Pubblicato il 13/03/2017. Ultima modifica il 13/03/2017 alle ore ...
AbbVie Inc.'s (ABBV - Free Report) shares were down 2.1% following the release of fourth quarter and full year 2016 results on Friday. Although earnings were in line with expectations, revenues fell short mainly due to Imbruvica and Viekira sales (Read ...
If the FDA were not in the hip pocket of pharmaceutical industry we would soon have biosimilar competition in USA. FDA is a part of the "swamp" needs draining. AbbVie has long since recovered development costs. This price increase is usurious. The ...
La multinazionale Usa ha investito in 7 anni cento milioni di euro nella penisola. Ora il polo di Latina produrrà i trattamenti di punta dell'azienda con una linea di distribuzione all'avanguardia. L'ad Greco: «Cresce l'impegno sulla ricerca: 60 studi ...
AbbVie is launching collaborations with two research institutions aimed at advancing cancer-focused research and discovery, the biopharma and its partners said today, continuing a series of efforts by the company to boost its oncology R&D. The value ...
Abbvie has backed out of a development program inked in June 2015 using Halozyme Therapeutics' ENHANZE™ platform technology and a tumor necrosis factor-alpha (TNF-alpha) target after target results were not achieved in a Phase I study.
... sviluppati con il supporto tecnologico di Omnys, AbbVie, grazie alla piattaforma digitale "AbbVie Care", dà al paziente la possibilità di essere supportato e accompagnato da una rete di operatori (dal medico al caregiver, dal personal tutor al call ...
Ablynx said today it will seek a new partner to develop its Phase III-ready rheumatoid arthritis (RA) candidate vobarilizumab after AbbVie opted not to license the compound following mixed Phase IIb results. Ablynx also said it will begin End-of-Phase ...
AbbVie Inc. (ABBV - Free Report) announced the submission of a supplemental New Drug Application (sNDA) for its blood cancer drug Imbruvica (ibrutinib) in the U.S.. AbbVie is looking for a label expansion of Imbruvica to include the treatment of ...
AbbVie Inc. (ABBV - Free Report) announced positive results from the phase IIIb study, Garnet, on a combination of its hepatitis drugs Viekirax (ombitasvir/paritaprevir/ritonavir tablets) and Exviera (dasabuvir tablets) for the treatment of patients ...
Amgen, Inc. (AMGN - Free Report) today announced the approval of Amjevita (adalimumab-atto), a biosimilar version to AbbVie Inc.'s (ABBV - Free Report) rheumatoid arthritis (RA) drug Humira. Amjevita has been approved for the same indications that ...
AbbVie will develop and commercialize BioArctic's portfolio of antibodies directed against α-synuclein for Parkinson's disease and other potential indications through a collaboration whose value was not disclosed. BioArctic, a Karolinska Development ...
Biotechnology drugmaker AbbVie Inc. filed a lawsuit seeking to block Amgen Inc. from selling a copy of the arthritis medicine Humira, its top seller. Amgen's proposed copy would infringe at least 10 patents, AbbVie said as it reserved the right to ...
North Chicago, IL-based AbbVie Inc. (ABBV - Free Report) is best known for its autoimmune disease drug, Humira. Other key products include Imbruvica (cancer) and Viekira Pak (hepatitis C virus (HCV) treatment). Humira, the company's flagship product ...
AbbVie and Bristol-Myers Squibb (BMS) said today they will launch an oncology clinical collaboration to assess two combination treatments for relapsed, extensive-stage, small-cell lung cancer (SCLC). The value of the Phase I/II clinical collaboration ...
Copycats of AbbVie's Humira and Amgen's Enbrel may soon win FDA approval. AbbVie's ABBV -0.49% Humira and Amgen's AMGN -0.49% Enbrel are two of the top drugs in the world by sales. Combined, the anti-inflammatory therapies for conditions like ...
Amgen Inc.'s biosimilar version of the arthritis drug Humira cleared a regulatory hurdle, bringing it closer to entering the U.S. market and providing competition that could lower prices for AbbVie Inc.'s best-selling treatment. A panel of Food and ...
DUBLIN – Ablynx NV's anti-interleukin-6-receptor (IL-6R) inhibitor, vobarilizumab (ALX-0061), demonstrated equivalent efficacy to the incumbent, Actemra (tocilizumab), in a phase IIb monotherapy trial in rheumatoid arthritis (RA). Some investors liked ...
AbbVie Inc. (ABBV - Free Report) and Johnson & Johnson's (JNJ - Free Report) Imbruvica got a fourth Breakthrough Therapy Designation (BTD), this time for a non-cancer indication. The FDA granted BTD to Imbruvica for the treatment of chronic ...
Infinity Pharmaceuticals said today it will eliminate 58% of its workforce—100 employees—and shut down several clinical trials in a restructuring touched off by the end of a nearly 2-year-old collaboration with AbbVie to co-develop the cancer ...
1) AbbVie's pipeline is better appreciated by the market following the company's R&D day on June 1 and data disclosures at ASCO over the past weekend. (2) In the wake of the recent intellectual property rights institution, we are more concerned that ...
Earlier today AbbVie (ABBV, NEUTRAL, $65.00) had data from its Ph. 1a/b trial with Rovalpituzumab Tesirine (RovaT) in small cell lung cancer (SCLC) presented by Dr. Charles Rudin from MSKCC at the American Society for Clinical Oncology conference in ...
Highly touted acquisitions often disappoint investors. They just usually take more than a month and change to do so. In late April, AbbVie announced it was paying $5.8 billion for Stemcentrx and its lead lung-cancer drug Rova-T. It was a big payout for ...
